Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 13-14/2014

01.07.2014 | case report

Dornase alpha inhalations as a treatment option for recurrent lower respiratory tract infections in a child with Sotos syndrome

verfasst von: MD Philipp Eickhoff, MD Tamas Fazekas, MD Hans Wank, MD Ulrike Kastner

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 13-14/2014

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Recurrent episodes of lower respiratory tract infections (LRTIs) are a rare complication of muscular hypotonia in patients with Sotos syndrome. We report on a male child suffering from repeated LRTIs including bronchitis, pneumonia, and atelectasis during infancy despite inhalations with salbutamol and fluticasone combined with manual chest percussion therapy. After initiation of dornase alpha inhalations in addition to the current treatment, we observed an improvement in the respiratory symptoms as well as a reduction in the rate of hospitalizations and in the occurrence of LRTIs. We assume that dornase alpha inhalations, in combination with airway clearance techniques, reduced the viscosity of airway secretions and by this improved mucociliary clearance and coughing efficiency.
Literatur
1.
Zurück zum Zitat Sotos JF, Dodge PR, Muirhead D, et al. Cerebral gigantism in childhood. N Engl J Med. 1964;271:109–16. PubMedCrossRef Sotos JF, Dodge PR, Muirhead D, et al. Cerebral gigantism in childhood. N Engl J Med. 1964;271:109–16. PubMedCrossRef
3.
Zurück zum Zitat Schramm CM. Current concepts of respiratory complications of neuromuscular disease in children. Curr Opin Pediatr. 2000;12:203–7. PubMedCrossRef Schramm CM. Current concepts of respiratory complications of neuromuscular disease in children. Curr Opin Pediatr. 2000;12:203–7. PubMedCrossRef
4.
Zurück zum Zitat Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care. 2007;52(9):1176–97. PubMed Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care. 2007;52(9):1176–97. PubMed
5.
Zurück zum Zitat Anon. Summary of product characteristics: Pulmozyme. Hertfordshire, Roche Products Limited; 1996. Anon. Summary of product characteristics: Pulmozyme. Hertfordshire, Roche Products Limited; 1996.
6.
Zurück zum Zitat Finder JD. Airway clearance modalities in neuromuscular disease. Paediatr Respir Rev. 2010;11:31–34. PubMedCrossRef Finder JD. Airway clearance modalities in neuromuscular disease. Paediatr Respir Rev. 2010;11:31–34. PubMedCrossRef
8.
Zurück zum Zitat De Boeck K, Vermeulen F, Vreys M, et al. Airway clearance techniques to treat acute respiratory disorders in previously healthy children: where is the evidence? Eur J Pediatr. 2008;167:607–12. PubMedCrossRef De Boeck K, Vermeulen F, Vreys M, et al. Airway clearance techniques to treat acute respiratory disorders in previously healthy children: where is the evidence? Eur J Pediatr. 2008;167:607–12. PubMedCrossRef
9.
Zurück zum Zitat Boitano LJ. Management of airway clearance in neuromuscular disease. Respir Care. 2006;51(8):913–22. PubMed Boitano LJ. Management of airway clearance in neuromuscular disease. Respir Care. 2006;51(8):913–22. PubMed
10.
Zurück zum Zitat Kravitz RM. Airway clearance in duchenne muscular dystrophy. Pediatrics. 2009;123:S231–5. CrossRef Kravitz RM. Airway clearance in duchenne muscular dystrophy. Pediatrics. 2009;123:S231–5. CrossRef
11.
Zurück zum Zitat Boogaard R, de Jongste JC, Merkus P. Pharmacotherapy of impaired mucociliary clearance in non-CF pediatric lung disease. A review of the literature. Pediatr Pulmonol. 2007;42:989–1001. PubMedCrossRef Boogaard R, de Jongste JC, Merkus P. Pharmacotherapy of impaired mucociliary clearance in non-CF pediatric lung disease. A review of the literature. Pediatr Pulmonol. 2007;42:989–1001. PubMedCrossRef
12.
Zurück zum Zitat Smyth AR, Barbato A, Beydon N, et al. Respiratory medicines for children: current evidence, unlicensed use and research priorities. Eur Respir J. 2010;35:247–65. PubMedCrossRef Smyth AR, Barbato A, Beydon N, et al. Respiratory medicines for children: current evidence, unlicensed use and research priorities. Eur Respir J. 2010;35:247–65. PubMedCrossRef
13.
Zurück zum Zitat Lesic I, Maurer E, Strippoli MP, et al. Primäre Ziliendyskinesie in Österreich. Wien Klin Wochenschr. 2009;121:616–22. PubMedCrossRef Lesic I, Maurer E, Strippoli MP, et al. Primäre Ziliendyskinesie in Österreich. Wien Klin Wochenschr. 2009;121:616–22. PubMedCrossRef
14.
15.
Zurück zum Zitat Eickhoff P, Fazekas T, Pötschger U, et al. Effect of treatment with dornase alpha on outcome of late-onset non-infectious pulmonary complications after paediatric allogeneic haematopoietic stem cell transplantation. Bone Marrow Transpl. 2010;45:S1–77. CrossRef Eickhoff P, Fazekas T, Pötschger U, et al. Effect of treatment with dornase alpha on outcome of late-onset non-infectious pulmonary complications after paediatric allogeneic haematopoietic stem cell transplantation. Bone Marrow Transpl. 2010;45:S1–77. CrossRef
16.
Zurück zum Zitat Christopher F, Chase D, Stein K, Milne R. rhDNase therapy for the treatment of cystic fibrosis patients with mild to moderate lung disease. J Clin Pharm Ther. 1999;24:415–26. PubMedCrossRef Christopher F, Chase D, Stein K, Milne R. rhDNase therapy for the treatment of cystic fibrosis patients with mild to moderate lung disease. J Clin Pharm Ther. 1999;24:415–26. PubMedCrossRef
17.
Zurück zum Zitat Panitch HB. Respiratory issues in the management of children with neuromuscular disease. Respir Care. 2006;51(8):885–95. PubMed Panitch HB. Respiratory issues in the management of children with neuromuscular disease. Respir Care. 2006;51(8):885–95. PubMed
18.
Zurück zum Zitat McKenzie SG, Chowdhury S, Strandvik B, et al. Dornase alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis. Pediatr Pulmonol. 2007;42:928–37. PubMedCrossRef McKenzie SG, Chowdhury S, Strandvik B, et al. Dornase alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis. Pediatr Pulmonol. 2007;42:928–37. PubMedCrossRef
Metadaten
Titel
Dornase alpha inhalations as a treatment option for recurrent lower respiratory tract infections in a child with Sotos syndrome
verfasst von
MD Philipp Eickhoff
MD Tamas Fazekas
MD Hans Wank
MD Ulrike Kastner
Publikationsdatum
01.07.2014
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 13-14/2014
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-014-0552-2